WIL2-NS细胞
细胞类型： B**细胞
是否是肿瘤细胞： 0
物种来源： 人
年限： 5 years
ATCC Number： CRL-8155™
相关**： 其他**
器官来源： 脾
运输方式： 冻存运输
生长状态： 悬浮生长
数量： 大量
细胞形态： **样
Designations: WIL2-NS
WIL2-NS细胞Depositors: TA Coons
Biosafety Level: 2
Shipped: frozen
Medium & Serum: See Propagation
Growth Properties: suspension
Organism: Homo sapiens
Morphology: lymphoblast
Source: Organ: spleen
Disease: hereditary spherocytosis
Cell Type: B lymphocyte;
Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. WIL2-NS细胞Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Applications: transfection host (Roche Transfection Reagents)
DNA Profile (STR): Amelogenin: X,Y
CSF1PO: 11,12
D13S317: 11
D16S539: 11,12
D5S818: 12,13
D7S820: 9,12
F13A01: 6,7
F13B: 10
FESFPS: 11,12
LPL: 9,10
THO1: 8,9.3
TPOX: 8,11
vWA: 17,20
Age: 5 years
Gender: male
Ethnicity: Caucasian
Comments: WIL2-NS细胞This line does not secrete immunoglobulin.
The line was derived from the WIL-2 B cell line.
Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Temperature: 37.0°C
Subculturing: Medium Renewal: Every 2 to 3 days
Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2 X 10 exp5 cells/ml and maintain between 1 X 10 exp5 and 1 X 10 exp6 cells/ml.
Preservation: culture medium 95%; DMSO, 5%
Related Products: Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2001
recommended serum:ATCC 30-2020
References: 22789: Levy JA, et al. WIL2-NS细胞Human lymphoblastoid lines from lymph node and spleen. Cancer 22: 517-524, 1968. PubMed: 5673231
23199: Alspaugh MA, Tan EM. Antibodies to cellular antigens in Sjogren's syndrome. J. Clin. Invest. 55: 1067-1073, 1975. PubMed: 804494
26176: Vaughan JH, et al. Synthetic polypeptides and antibodies related to epstein-barr virus nuclear antigen. US Patent 4,654,419 dated Mar 31 1987
26177: Vaughan JH, et al. Assay for Epstein-Barr virus infection with solid phase bound synthetic polypeptides. US Patent 5,116,725 dated May 26 1992
26178: Vaughan JH, et al. Assay of anti-Epstein-Barr virus nuclear antigen antibodies with synthetic polypeptides. US Patent 5,122,448 dated Jun 16 1992
26179: Levy JA, et al. Further characterization of the WI-L1 and WI-L2 lymphoblastoid lines. J. Natl. Cancer Inst. 46: 647-654, 1971. PubMed: 4323138
